3 min read
By Dr. Maria K. Jimmy
Did your favourite celebrity suddenly look “transformed”?
Was it discipline… or was it Ozempic?
Before we romanticise the needle, let’s understand what this drug actually is — beyond the headlines.
Diabetes Drug or Weight Loss Shortcut?
Ozempic is the brand name for semaglutide, a drug from a class called GLP-1 receptor agonists.
In India, it is approved by the Central Drugs Standard Control Organisation (CDSCO) for one purpose: blood sugar control in Type 2 Diabetes Mellitus.
To be absolutely clear: Ozempic is not approved in India as a weight loss drug.
When semaglutide is used purely for weight loss in a person without diabetes, it becomes off-label use.
Off-label prescribing is legally permissible, but it requires:
- careful medical judgement
- documented discussion of risks
- informed consent
Clinical guidelines further suggest that pharmacological weight-loss therapy should follow failure of structured diet and lifestyle measures, and typically apply to individuals with:
- BMI above 30 kg/m²
- BMI above 27 kg/m² with obesity-related conditions
That is the medical framework.
However, the reality unfolding outside clinics often looks very different.
How Ozempic Tricks Your Appetite (The GLP-1 Science Made Simple)
After you eat, your intestines naturally release hormones (GLP-1) that tell your brain, “We are full.”
Semaglutide mimics this hormone. It does two things:
- Slows gastric emptying – Food sits in your stomach longer.
- Acts on the hypothalamus – It reduces the reward signal from eating.
The result is simple:
You feel full quickly, cravings quieten, and you naturally eat less.
Ozempic in India: What Makes Our Risk Different?
In India, this drug carries specific concerns.
1. Slender Frame, Low Muscle Reserve
Many Indians have what is informally called “normal weight obesity” — a lean appearance with higher visceral fat and lower muscle mass.
Using a potent GLP-1 agonist without supervision can accelerate muscle loss.
Weight drops, yes. But lean body mass, particularly skeletal muscle, may decline as well.
2. Gastroparesis Risk
Clinicians in India observe a high prevalence of functional dyspepsia — chronic bloating, fullness, slow digestion.
Because this drug deliberately slows stomach emptying, it can worsen these symptoms and, in susceptible individuals, contribute to gastroparesis — where the stomach struggles to move food forward properly.
3. Thyroid Concerns
GLP-1 agonists are contraindicated in anyone with a personal or family history of:
- Medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
This matters because, in many Indian clinical settings, baseline thyroid tests, including calcitonin levels, are not routinely performed before starting therapy.
The Weight Comeback Nobody Talks About
Semaglutide has a half-life of approximately one week.
It stays in your system.
But once you stop injecting — whether due to cost or after reaching your goal weight — hunger returns.
But it does not return “normally.”
Ghrelin (the hunger hormone) often rebounds with a vengeance. Patients report “food noise” so loud it is distressing. The weight comes back, frequently exceeding the original weight.
This is documented. In a 2021 JAMA study, participants who discontinued semaglutide regained nearly two-thirds of the weight they had lost within one year.
When Nausea Isn’t Just Nausea
Authoritative sources (listed in the References) identify gastrointestinal symptoms as the most common adverse effects of GLP-1 receptor agonists.
These include:
- Persistent nausea and vomiting
- Diarrhoea or severe constipation
- Abdominal distension and discomfort
- Delayed gastric emptying
- Rare but serious risks such as pancreatitis
In clinical practice, this can look like:
- Nausea that does not settle despite medication
- Bloating so marked it mimics fluid accumulation
- Constipation severe enough to require hospital care
In fact, these effects follow the drug’s design. So digestive symptoms are a predictable consequence of its mechanism.
Who Really Pays the Price?
For a diabetic patient who genuinely needs it for glycaemic control, supply shortages that are driven by cosmetic demand carry real consequences.
In simple terms:
A patient with uncontrolled diabetes may struggle to access essential medicine because someone without diabetes wanted to drop a dress size.
Before You Inject: A Final Word
Ozempic is an important medical advancement when used for its intended purpose.
- In diabetes, it treats a clearly defined metabolic problem.
- In cosmetic weight loss, it addresses a manufactured insecurity.
That distinction matters.
Sustainable weight management still depends on lifestyle habits, which are explained in Daily Habits That Help With Weight Management.
Every prescription carries responsibility, both in dose and clinical judgement. Without these, a powerful drug becomes simply another way our culture convinces people they are not enough as they are.
The molecule is never the issue here.
The context is.
References & Further Reading
- Harrison’s Principles of Internal Medicine, 21st ed.
- Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed.
- Davidson’s Principles and Practice of Medicine, 24th ed.
- API Textbook of Medicine, 12th ed.
- Rubino D et al. STEP 4 Trial. JAMA. 2021.
Author’s Note: Clinical data in this article are drawn from the listed references; contextual observations are the author’s own.
Image Note: The accompanying image is AI-generated and does not represent a real person.
You may wish to read these next:
Dr. Maria K. Jimmy 